Some larger companies are also involved, with GlaxoSmithKline extending their longstanding biosecurity portfolio to include the Ebola vaccine ChAd3 developed at the National Institute of Allergy and Infectious Diseases (NIAID) with Okairos, a Swiss company that GSK acquired in 2013. Earlier this month, NIH released encouraging Phase I safety and antibody response data to optimize the dose of the vaccine.